Companies › Biocad
18 active drug programs in 27 registered trials: 15 Phase 3, 7 Phase 1, 5 Phase 2; Immunology, Oncology, Neurology, Hematology; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Nivolumab (BCD-263) Programmed cell death protein 1 inhibitor | PDCD1 | Phase 3 | Advanced Melanoma | Jan 2027 |
| nurulimab | – | Phase 3 | Melanoma; Melanoma Stage III | Jan 2027 |
| divozilimab anti-CD20 monoclonal antibody | MS4A1 | Phase 3 | Neuromyelitis Optica Spectrum Disorders; Systemic Scleroderma | Feb 2027 |
| ANB-002 (arvenacogene sanparvovec) Adeno-associated viral vector carrying the FIX gene | F9 | Phase 3 | Hemophilia B | Apr 2027 |
| BCD-180 anti-TRBV9 monoclonal antibody | TRBV9 | Phase 3 | Axial Spondyloarthritis | Jun 2027 |
| BCD-131 (pegdarbepoetin beta) Erythropoietin receptor (EPOR) agonist; pegylated darbepoetin beta | EPOR | Phase 3 | Anemia | Oct 2027 |
| Levilimab Interleukin-6 receptor alpha subunit inhibitor | IL6R | Phase 3 | Rheumatoid Arthritis | Dec 2027 |
| Netakimab IL-17A inhibitor monoclonal antibody | IL17A | Phase 3 | Plaque Psoriasis | Feb 2028 |
| BCD-248 anti-BCMA antibody-based therapy | – | Phase 3 | Myeloma Multiple; Relapsed/Refractory Multiple Myeloma | Jul 2028 |
| BCD-281 anti-CD20 monoclonal antibody | CD20 | Phase 3 | Relapsing-remitting Multiple Sclerosis (RRMS) | Dec 2028 |
| Pertuzumab (BCD-178) Receptor protein-tyrosine kinase erbB-2 inhibitor | ERBB2 | Phase 3 | Breast Cancer | – |
| prolgolimab anti-PD-L1 monoclonal antibody | CD274 | Phase 3 | Melanoma | – |
| BCD-261 Anti-TL1A human monoclonal antibody | TNFSF15, TL1A | Phase 2 | Ulcerative Colitis (UC); Crohn's Disease (CD); Healthy | Jan 2027 |
| BCD-236 | – | Phase 2 | Triple Negative Breast Cancer | May 2027 |
| ANB-004 Adeno-associated viral vector carrying the SMN gene | SMN1 | Phase 1 | Spinal Muscular Atrophy (SMA) | Aug 2030 |
| ANB-010 Adeno-associated viral vector carrying the FVIII gene | F8 | Phase 1 | Hemophilia A | Jun 2033 |
| Litifilimab (BCD-256) C-type lectin domain family 4 member C inhibitor | CLEC4C | Phase 1 | Systemic Lupus Erthematosus | – |
| Rituximab B-lymphocyte antigen CD20 binding agent | MS4A1 | Phase 1 | Systemic Lupus Erthematosus | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05732805 | nurulimab | Phase 3 | Melanoma | Oncology | Jun 2024 |
| NCT05732805 | prolgolimab | Phase 3 | Melanoma | Oncology | Jun 2024 |
| NCT05730699 | divozilimab | Phase 3 | Neuromyelitis Optica Spectrum Disorders | Neurology | Jan 2025 |
| NCT06715540 | BCD-261 | Phase 1 | Healthy | Immunology | Feb 2025 |
| NCT05802225 | Pertuzumab (BCD-178) | Phase 3 | Breast Cancer | Oncology | Jun 2025 |
| NCT07136389 | Litifilimab (BCD-256) | Phase 1 | Systemic Lupus Erthematosus | Immunology | Jan 2026 |
| NCT07136389 | Rituximab | Phase 1 | Systemic Lupus Erthematosus | Immunology | Jan 2026 |
| NCT07080034 | BCD-261 | Phase 2 | Ulcerative Colitis (UC) | Immunology | Jan 2027 |
| NCT06112808 | Nivolumab (BCD-263) | Phase 1 | Advanced Melanoma | Oncology | Jan 2027 |
| NCT05751928 | nurulimab | Phase 3 | Melanoma Stage III | Oncology | Jan 2027 |
| NCT05751928 | nurulimab | Phase 3 | Melanoma Stage III | Oncology | Jan 2027 |
| NCT05726630 | divozilimab | Phase 3 | Systemic Scleroderma | Immunology | Feb 2027 |
| NCT06640530 | Nivolumab (BCD-263) | Phase 3 | Advanced Melanoma | Oncology | Mar 2027 |
| NCT06700096 | ANB-002 (arvenacogene sanparvovec) | Phase 3 | Hemophilia B | Hematology | Apr 2027 |
| NCT07078994 | BCD-261 | Phase 2 | Crohn's Disease (CD) | Immunology | May 2027 |
| NCT07108309 | BCD-236 | Phase 2 | Triple Negative Breast Cancer | Oncology | May 2027 |
| NCT05445076 | BCD-180 | Phase 2 | Axial Spondyloarthritis | Immunology | Jun 2027 |
| NCT07119372 | BCD-131 (pegdarbepoetin beta) | Phase 3 | Anemia | Genitourinary | Oct 2027 |
| NCT05800327 | Levilimab | Phase 3 | Rheumatoid Arthritis | Immunology | Dec 2027 |
| NCT06640517 | Netakimab | Phase 3 | Plaque Psoriasis | Immunology | Feb 2028 |
| NCT06333210 | BCD-180 | Phase 3 | Axial Spondyloarthritis | Immunology | Feb 2028 |
| NCT07742215 | BCD-248 | Phase 3 | Myeloma Multiple | Oncology | Jul 2028 |
| NCT06668792 | BCD-248 | Phase 2 | Relapsed/Refractory Multiple Myeloma | Oncology | Jul 2028 |
| NCT07321093 | BCD-281 | Phase 3 | Relapsing-remitting Multiple Sclerosis (RRMS) | Neurology | Dec 2028 |
| NCT06120582 | ANB-002 (arvenacogene sanparvovec) | Phase 1 | Hemophilia B | Hematology | Nov 2029 |
| NCT05747261 | ANB-004 | Phase 1 | Spinal Muscular Atrophy (SMA) | Neurology | Aug 2030 |
| NCT06185335 | ANB-010 | Phase 1 | Hemophilia A | Hematology | Jun 2033 |
Celltrion Sinocelltech Taizhou Mabtech Pharmaceutical Beijing VDJBio R-Pharm
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.